AVITA Medical (RCEL) Common Equity (2018 - 2025)
AVITA Medical filings provide 8 years of Common Equity readings, the most recent being -$16.6 million for Q4 2025.
- On a quarterly basis, Common Equity fell 470.08% to -$16.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$16.6 million, a 470.08% decrease, with the full-year FY2025 number at -$16.6 million, down 470.08% from a year prior.
- Common Equity hit -$16.6 million in Q4 2025 for AVITA Medical, down from -$6.7 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $118.9 million in Q1 2021 to a low of -$16.6 million in Q4 2025.
- Median Common Equity over the past 5 years was $65.8 million (2023), compared with a mean of $55.2 million.
- Biggest five-year swings in Common Equity: surged 75.55% in 2021 and later crashed 470.08% in 2025.
- AVITA Medical's Common Equity stood at $104.6 million in 2021, then decreased by 19.01% to $84.7 million in 2022, then tumbled by 42.11% to $49.1 million in 2023, then plummeted by 90.83% to $4.5 million in 2024, then crashed by 470.08% to -$16.6 million in 2025.
- The last three reported values for Common Equity were -$16.6 million (Q4 2025), -$6.7 million (Q3 2025), and -$12.9 million (Q2 2025) per Business Quant data.